Figure 1.
Mean (SE) change from baseline in FACIT-Fatigue score throughout pivotal (part A) and 2-year extension (part B) phases of CARDINAL, and at the ET/SFU follow-up visit, 9 weeks after cessation of sutimlimab treatment. BL, baseline.

Mean (SE) change from baseline in FACIT-Fatigue score throughout pivotal (part A) and 2-year extension (part B) phases of CARDINAL, and at the ET/SFU follow-up visit, 9 weeks after cessation of sutimlimab treatment. BL, baseline.

Close Modal

or Create an Account

Close Modal
Close Modal